The North America In Situ Hybridization Market would witness market growth of 6.3% CAGR during the forecast period (2022-2028).
One of the fundamental techniques in developmental biology is in situ hybridization (ISH), which can enable the visualization and even quantification of therapeutically essential molecules in a morphological context. It is among the most critical methods for observing how genes are expressed at the cellular level in tissues. The first step in comprehending how genes operate is the detection of patterns of gene expression in tissues, which may provide crucial spatial and temporal information.
Nonradioactive probes are preferred over radioactive ones for regular ISH in pathology since the latter require laborious usage. In identifying relatively numerous genes in a single cell, nonisotopic approaches to enhance fluorescence or colorimetric detection offer results with a sensitivity equivalent to that produced by radioactive labeling. In combination with streptavidin-nanogold-silver staining, Super-sensitive ISH may be used to achieve even higher sensitivity when detecting single copies of specific mRNAs. In any instance, the primary determinant of sensitivity is the chosen detection method.
The Canadian government supports groups like the Canadian Partnership Against Cancer in the fight against this illness (CPAC). To continue CPAC's efforts in cancer management, the government has announced intentions to contribute $250 million over five years. With the Canadian Institutes of Health Research, the government is also making large expenditures in cancer research, investing more than $159 million in only 2009-10 to develop therapies and look for a cure. The market for in situ hybridization is anticipated to have considerable expansion in the area over the projected period due to the rising incidence of cancer across North American countries and the rising government funding for the disease's treatment.
The US market dominated the North America In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $554.5 million by 2028.The Canada market is poised to grow at a CAGR of 8.7% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 7.8% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
One of the fundamental techniques in developmental biology is in situ hybridization (ISH), which can enable the visualization and even quantification of therapeutically essential molecules in a morphological context. It is among the most critical methods for observing how genes are expressed at the cellular level in tissues. The first step in comprehending how genes operate is the detection of patterns of gene expression in tissues, which may provide crucial spatial and temporal information.
Nonradioactive probes are preferred over radioactive ones for regular ISH in pathology since the latter require laborious usage. In identifying relatively numerous genes in a single cell, nonisotopic approaches to enhance fluorescence or colorimetric detection offer results with a sensitivity equivalent to that produced by radioactive labeling. In combination with streptavidin-nanogold-silver staining, Super-sensitive ISH may be used to achieve even higher sensitivity when detecting single copies of specific mRNAs. In any instance, the primary determinant of sensitivity is the chosen detection method.
The Canadian government supports groups like the Canadian Partnership Against Cancer in the fight against this illness (CPAC). To continue CPAC's efforts in cancer management, the government has announced intentions to contribute $250 million over five years. With the Canadian Institutes of Health Research, the government is also making large expenditures in cancer research, investing more than $159 million in only 2009-10 to develop therapies and look for a cure. The market for in situ hybridization is anticipated to have considerable expansion in the area over the projected period due to the rising incidence of cancer across North American countries and the rising government funding for the disease's treatment.
The US market dominated the North America In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $554.5 million by 2028.The Canada market is poised to grow at a CAGR of 8.7% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 7.8% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
By End Use
- Research & Diagnostic Laboratories
- Academic Institutes
- CROs
- Others
By Application
- Cancer
- Cytogenetics
- Developmental Biology
- Infectious Diseases
- Others
By Product
- Instruments
- Kits & Probes
- Software
- Services
By Probe
- DNA
- RNA
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Abbott Laboratories
- PerkinElmer, Inc
- Agilent Technologies, Inc
- Merck Group
- Bio-Rad Laboratories, Inc
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd
- Neogenomics, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America In Situ Hybridization Market, by Technology
1.4.2 North America In Situ Hybridization Market, by End Use
1.4.3 North America In Situ Hybridization Market, by Application
1.4.4 North America In Situ Hybridization Market, by Product
1.4.5 North America In Situ Hybridization Market, by Probe
1.4.6 North America In Situ Hybridization Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America In Situ Hybridization Market by Technology
3.1 North America Fluorescent In Situ Hybridization (FISH) Market by Country
3.2 North America Chromogenic In Situ Hybridization (CISH) Market by Country
Chapter 4. North America In Situ Hybridization Market by End-use
4.1 North America Research & Diagnostic Laboratories Market by Country
4.2 North America Academic Institutes Market by Country
4.3 North America CROs Market by Country
4.4 North America Others Market by Country
Chapter 5. North America In Situ Hybridization Market by Application
5.1 North America Cancer Market by Country
5.2 North America Cytogenetics Market by Country
5.3 North America Developmental Biology Market by Country
5.4 North America Infectious Diseases Market by Country
5.5 North America Others Market by Country
Chapter 6. North America In Situ Hybridization Market by Product
6.1 North America Instruments Market by Country
6.2 North America Kits & Probes Market by Country
6.3 North America Software Market by Country
6.4 North America Services Market by Country
Chapter 7. North America In Situ Hybridization Market by Probe
7.1 North America DNA Market by Country
7.2 North America RNA Market by Country
Chapter 8. North America In Situ Hybridization Market by Country
8.1 US In Situ Hybridization Market
8.1.1 US In Situ Hybridization Market by Technology
8.1.2 US In Situ Hybridization Market by End-use
8.1.3 US In Situ Hybridization Market by Application
8.1.4 US In Situ Hybridization Market by Product
8.1.5 US In Situ Hybridization Market by Probe
8.2 Canada In Situ Hybridization Market
8.2.1 Canada In Situ Hybridization Market by Technology
8.2.2 Canada In Situ Hybridization Market by End-use
8.2.3 Canada In Situ Hybridization Market by Application
8.2.4 Canada In Situ Hybridization Market by Product
8.2.5 Canada In Situ Hybridization Market by Probe
8.3 Mexico In Situ Hybridization Market
8.3.1 Mexico In Situ Hybridization Market by Technology
8.3.2 Mexico In Situ Hybridization Market by End-use
8.3.3 Mexico In Situ Hybridization Market by Application
8.3.4 Mexico In Situ Hybridization Market by Product
8.3.5 Mexico In Situ Hybridization Market by Probe
8.4 Rest of North America In Situ Hybridization Market
8.4.1 Rest of North America In Situ Hybridization Market by Technology
8.4.2 Rest of North America In Situ Hybridization Market by End-use
8.4.3 Rest of North America In Situ Hybridization Market by Application
8.4.4 Rest of North America In Situ Hybridization Market by Product
8.4.5 Rest of North America In Situ Hybridization Market by Probe
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.2 Abbott Laboratories
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PerkinElmer, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Agilent Technologies, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.6 Bio-Rad laboratories, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expenses
9.7 Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Danaher Corporation (Leica Biosystems)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.9 F. Hoffmann-La Roche Ltd.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.10. Neogenomics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd.
- Neogenomics, Inc.
Methodology
LOADING...
